At 5.5% CAGR, Middle East & Africa Custom Antibody Services Market is Projected to be Worth US$ 25.54 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa custom antibody services market was valued at US$ 16.65 million in 2023 and is expected to reach US$ 25.54 million by 2031, registering a CAGR of 5.5% from 2023 to 2031. Technological advancements using recombinant antibodies and increasing prevalence of chronic diseases among the critical factors attributed to the Middle East & Africa custom antibody services market expansion.

Recombinant antibody engineering has a wide scope of potential for drug developers and researchers to create specific molecules with specific attributes ideally suited for treating specific diseases. Several drug developers are already using AI technologies in the prediction and analysis of potential therapeutics from antibody sequences, using algorithms to assess their potential before production has commenced. For instance, Foundation Medicine develops, manufactures, and sells genomic profiling assays on the basis of next-generation sequencing technology for solid tumors, hematologic malignancies, and sarcomas that can be utilized to match patients with targeted therapies, immunotherapies, and clinical trial options. Such companies also partner with the biopharma industry to help discover, develop, and distribute the next breakthrough treatments for patients. The Medicines Discovery Catapult is testing (on a computer) an in silico pipeline for identifying new molecules for cancer treatment; for example, applying AI to find new disease drivers as well as candidate drugs for lung cancer. Thus, technological advancements using recombinant antibodies are expected to bring new trends into the custom antibody services market in the coming years.

On the contrary, high costs and complexities associated with antibody production using transgenic animals hamper the growth of Middle East & Africa custom antibody services market.

Based on product type, the Middle East & Africa custom antibody services market is segmented into monoclonal, polyclonal hybridoma, recombinant antibody, and others. The monoclonal segment held 49.5% share of the Middle East & Africa custom antibody services market in 2023, amassing US$ 8.25 million. It is projected to garner US$ 12.27 million by 2031 to expand at 5.1% CAGR during 2023-2031.

Based on service type, the Middle East & Africa custom antibody services market is segmented into antibody discovery and development, antibody production services, and others. The antibody discovery and development segment held 71.0% share of the Middle East & Africa custom antibody services market in 2023, amassing US$ 11.82 million. It is projected to garner US$ 18.23 million by 2031 to expand at 5.6% CAGR during 2023-2031.

Based on application, the Middle East & Africa custom antibody services market is segmented into immunohistochemistry, western blot & IP, ELISA, fluorescence-activated cell sorting, mass spectrometry, and others. The ELISA segment held 40.1% share of the Middle East & Africa custom antibody services market in 2023, amassing US$ 6.67 million. It is projected to garner US$ 9.93 million by 2031 to expand at 5.1% CAGR during 2023-2031.

Based on disease indication, the Middle East & Africa custom antibody services market is segmented into oncology, infectious diseases, immunology, cardiovascular diseases, and others. The oncology segment held 49.8% share of the Middle East & Africa custom antibody services market in 2023, amassing US$ 8.30 million. It is projected to garner US$ 13.17 million by 2031 to expand at 5.9% CAGR during 2023-2031.

Based on source, the Middle East & Africa custom antibody services market is segmented into chicken, rabbits, rats, guinea pigs, mouse or humanized mice, and others. The mouse or humanized mice segment held 39.5% share of the Middle East & Africa custom antibody services market in 2023, amassing US$ 6.57 million. It is projected to garner US$ 9.76 million by 2031 to expand at 5.1% CAGR during 2023-2031. The mouse or humanized mice segment is further sub segmented into monoclonal antibody platform, BsAB discovery platform, bispecific ADC platform, TCR-mimic antibody platform, Anti-GPCR antibody technology platform, and others.

Based on end user, the Middle East & Africa custom antibody services market is segmented into life science industry, pharmaceutical & biotech companies, academic & research institutes, and contract research organizations. The life science industry segment held 36.4% share of the Middle East & Africa custom antibody services market in 2023, amassing US$ 6.05 million. It is projected to garner US$ 9.19 million by 2031 to expand at 5.4% CAGR during 2023-2031.

Based on country, the Middle East & Africa custom antibody services market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia held 41.7% share of Middle East & Africa custom antibody services market in 2023, amassing US$ 6.95 million. It is projected to garner US$ 11.35 million by 2031 to expand at 6.3% CAGR during 2023-2031.

Key players operating in the custom antibody services market are Thermo Fisher Scientific Inc; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody (A&G Pharmaceutical, Inc.; Biocytogen Pharmaceuticals Beijing Co Ltd; Abgenex; Creative Biolabs Inc; Agilent Technologies Inc; Bioklone; and Scantibodies Laboratory, Inc., among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com